Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Inc. (LRMR) is a clinical-stage biopharmaceutical company focused on developing treatments for complex rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania and was founded in 2018.

Larimar Therapeutics' lead drug candidate, CTI-1601, is being developed for Friedreich's ataxia (FA), a rare inherited disorder that causes progressive damage to the nervous system, leading to movement problems and other complications. CTI-1601 is a recombinant fusion protein that increases frataxin expression in cells affected by FA.

Larimar is also developing several other product candidates for rare diseases, including compounds targeting Niemann-Pick disease Type C1 (NPC1), GM1 gangliosidosis, and infantile neuroaxonal dystrophy (INAD).

The company's development programs utilize proprietary protein replacement and gene therapy technologies that are designed to overcome the challenges associated with delivering therapies to the central nervous system.

Larimar Therapeutics is led by an experienced management team with a proven track record of success in drug development and commercialization. The company is backed by leading life science investors and has partnerships with academic institutions and other biotech companies.